| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Department of Surgery, Southern Illinois University School of Medicine, Springfield, Illinois.
Correspondence: Address correspondence and reprint requests to: Mokenge P. Malafa, MD, Department of Interdisciplinary Oncology, G. I. Tumor Program, H. Lee Moffitt Cancer Center & Research Institute, MRC-DRDIS, University of South Florida, 12902 Magnolia Dr., Tampa, FL 33612; Fax: 217-545-1793; E-mail: mmalafa{at}moffitt.usf.edu
Background: Relapse of melanoma after surgical treatment remains a significant clinical problem in need of novel therapies. Vitamin E succinate (VES) is a promising antitumor micronutrient. We evaluated the effect of VES on melanoma dormancy and angiogenesis.
Methods: B16F10 melanoma cells were allografted in mice. The effect of VES on melanoma dormancy was measured by monitoring tumor volume. Tumor vascularity was quantitated with CD31 immunostaining. The expression of vascular endothelial growth factor (VEGF), VEGF receptor 1, and VEGF receptor 2 in tumors was assessed by the intensity of immunostaining. VES effect on secreted VEGF protein and VEGF promoter activity was measured with enzyme-linked immunosorbent assay and transient transfection assay, respectively. Significance was determined by analysis of variance.
Results: VES promoted melanoma dormancy (P = .0019) and inhibited melanoma angiogenesis (P < .0001). VES also significantly suppressed the expression of VEGF, VEGF receptor 1, and VEGF receptor 2 in melanoma tumors (P < .0001). Melanoma VEGF secretion (P = .0077) and melanoma VEGF promoter activity (P < .05) were significantly inhibited by VES.
Conclusions: VES promotes melanoma dormancy and inhibits melanoma angiogenesis. The mechanism of the VES antiangiogenesis effect involves the inhibition of VEGF gene transcription. These findings support future studies of VES in the prevention of melanoma metastasis.
Key Words: Melanoma • Vitamin E succinate • Tumor dormancy • Angiogenesis • VEGF
This article has been cited by other articles:
 |
|
 |
|
  M. Shim and T. E. Eling Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism Mol. Cancer Ther., April 1, 2008; 7(4): 961 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-W. Shiau, J.-W. Huang, D.-S. Wang, J.-R. Weng, C.-C. Yang, C.-H. Lin, C. Li, and C.-S. Chen {alpha}-Tocopheryl Succinate Induces Apoptosis in Prostate Cancer Cells in Part through Inhibition of Bcl-xL/Bcl-2 Function J. Biol. Chem., April 28, 2006; 281(17): 11819 - 11825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Donapaty, S. Louis, E. Horvath, J. Kun, S. M. Sebti, and M. P. Malafa RRR-{alpha}-Tocopherol succinate down-regulates oncogenic Ras signaling. Mol. Cancer Ther., February 1, 2006; 5(2): 309 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Uzick Naturopathic Approaches Integr Cancer Ther, September 1, 2005; 4(3): 253 - 258. [PDF]
|
|
|
|
|
|
M. Stapelberg, N. Gellert, E. Swettenham, M. Tomasetti, P. K. Witting, A. Procopio, and J. Neuzil {alpha}-Tocopheryl Succinate Inhibits Malignant Mesothelioma by Disrupting the Fibroblast Growth Factor Autocrine Loop: MECHANISM AND THE ROLE OF OXIDATIVE STRESS J. Biol. Chem., July 8, 2005; 280(27): 25369 - 25376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Borek Dietary Antioxidants and Human Cancer Integr Cancer Ther, December 1, 2004; 3(4): 333 - 341. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
